arrow
A

Andrew J. Portuguese

Fred Hutchinson Cancer Center
H指数:13
被引数:1,035

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early treatment failure after ciltacabtagene autoleucel in multiple myeloma with high-risk features: implications for risk-informed care

具有高危特征的多发性骨髓瘤在应用cilta-cabtagene autoleucel治疗后早期失败:对风险知情护理的启示

2026-10-220
OAAI
Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium
2026-07-270
OA
Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma

快速峰值Cilta-cel扩增与多发性骨髓瘤中的迟发性神经毒性相关

Blood
IF23.1
2026-07-090
PRE
Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome

早期神经系统反应预测anakinra治疗免疫效应细胞相关神经毒性综合征的结局

2026-06-020
OAAI
Comparative economic analysis of B-cell maturation antigen-targeted bispecific antibodies in triple-class exposed relapsed/refractory multiple myeloma: linvoseltamab versus teclistamab and elranatamab

三药联合方案暴露后的复发/难治性多发性骨髓瘤中B细胞成熟抗原靶向双特异性抗体的比较经济分析:linvoseltamab与teclistamab和elranatamab的比较

2026-05-010
OA
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium

elranatamab治疗多发性骨髓瘤的真实世界结局: 来自美国多发性骨髓瘤免疫治疗联盟的多中心分析

2026-03-270
OAAI
The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma

系统性AL淀粉样变性伴发骨髓瘤中商业化BCMA靶向CAR T细胞疗法的安全性与有效性

2026-03-200
PREAI
Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma

髓外疾病与多发性骨髓瘤中B细胞成熟抗原CAR T细胞疗法后的严重毒性与相关。

2025-12-015
OA
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

外周髓外和骨旁浆细胞瘤对使用teclistamab治疗的多发性骨髓瘤患者治疗结局的影响:美国骨髓瘤免疫治疗联盟真实世界经验

2025-11-280
OAAI
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response

多发性骨髓瘤患者对特克替玛初始无应答后延迟应答的预测因子

2025-10-110
OAAI
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials

Gamma-分泌酶抑制剂对BCMA CAR-T疗法后多发性骨髓瘤结局的影响:两项I期试验的比较

2025-09-080
PRE
Opportunities to improve antibiotic stewardship, and identification of blood biomarkers associated with bacteremia following CAR-T cell therapy

改善抗生素合理使用的机会,以及CAR-T细胞疗法后菌血症相关血液生物标志物的鉴定

2025-07-310
PRE
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

接受过BCMA靶向疗法的复发/难治性多发性骨髓瘤患者中teclistamab的治疗效果:一项来自美国多发性骨髓瘤免疫治疗联盟的多中心研究

2025-06-250
OAAI
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the US Multiple Myeloma Immunotherapy Consortium

复发难治性多发性骨髓瘤(RRMM)老年患者接受teclistamab治疗后的结局:一项来自美国多发性骨髓瘤免疫治疗联盟的多中心研究

2025-05-090
OA
Corrigendum to Active Extramedullary Disease Predicts ICANS and Early ICAHT after CAR-T Therapy in Multiple Myeloma Transplantation and Cellular Therapy 31/2S (2025) S409

更正:活动性髓外病变预测CAR-T疗法后多发性骨髓瘤移植与细胞治疗中的ICANS和早期ICAHT 《移植与细胞治疗》31/2S (2025) S409

2025-04-120
PRE
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment

替卡妥莫单抗用于重度预治疗复发/难治性多发性骨髓瘤伴肾功能不全的患者

2025-04-100
OA